---
document_datetime: 2023-09-21 20:52:32
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/documents/all-authorised-presentations/epclusa-epar-all-authorised-presentations_en.pdf
document_name: epclusa-epar-all-authorised-presentations_en.pdf
version: success
processing_time: 0.8752641
conversion_datetime: 2025-12-23 03:29:36.756137
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
| MA (EU) number   | (Invented) name   | Strength         | Pharmaceutical Form   | Route of Administration   | Immediate Packaging   | Pack size   |
|------------------|-------------------|------------------|-----------------------|---------------------------|-----------------------|-------------|
| EU/1/16/1116/001 | Epclusa           | 400 mg / 100 mg  | Film-coated tablet    | Oral use                  | bottle (HDPE)         | 28 tablets  |
| EU/1/16/1116/002 | Epclusa           | 200 mg / 50 mg   | Film-coated tablet    | Oral use                  | bottle (HDPE)         | 28 tablets  |
| EU/1/16/1116/003 | Epclusa           | 150 mg / 37.5 mg | Coated granules       | Oral use                  | sachet (PET/alu/PE)   | 28 sachets  |
| EU/1/16/1116/004 | Epclusa           | 200 mg / 50 mg   | Coated granules       | Oral use                  | sachet (PET/alu/PE)   | 28 sachets  |